DFFN Stock Overview
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen.
Diffusion Pharmaceuticals Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.14|
|52 Week High||US$23.00|
|52 Week Low||US$4.64|
|1 Month Change||23.05%|
|3 Month Change||-3.46%|
|1 Year Change||-67.38%|
|3 Year Change||-73.87%|
|5 Year Change||-99.41%|
|Change since IPO||-99.59%|
Recent News & Updates
We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth CarefullyFeb 25
Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In GrowthNov 12
We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn RateJun 25
We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash WiselyMar 08
Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn SituationNov 23
|DFFN||US Biotechs||US Market|
Return vs Industry: DFFN underperformed the US Biotechs industry which returned -10.2% over the past year.
Return vs Market: DFFN underperformed the US Market which returned -14.8% over the past year.
|DFFN Average Weekly Movement||9.9%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: DFFN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: DFFN's weekly volatility (10%) has been stable over the past year.
About the Company
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Diffusion Pharmaceuticals Inc. Fundamentals Summary
|DFFN fundamental statistics|
Is DFFN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DFFN income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-7.35|
|Net Profit Margin||0.00%|
How did DFFN perform over the long term?See historical performance and comparison